Blockchain Registration Transaction Record

SignaBlok to Present Positive Preclinical Data on TREM-1 Inhibitor at 2025 AACR Annual Meeting

SignaBlok, Inc. to unveil groundbreaking preclinical data on macrophage-restricted TREM-1 inhibitor at 2025 AACR Annual Meeting. Exciting advancements in pancreatic cancer treatment with potential implications for other hard-to-treat tumors. Learn more about SignaBlok's innovative approach to inflammation-associated diseases.

SignaBlok to Present Positive Preclinical Data on TREM-1 Inhibitor at 2025 AACR Annual Meeting

This news matters as SignaBlok's innovative approach could lead to improved treatments for pancreatic cancer and other solid tumors. The development of new therapies targeting inflammation-associated diseases could significantly impact patient outcomes and survival rates.

BlockchainDetails
Contract Address0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71
Transaction ID0xab9ba0a4ac2a884b2d6afc7551409aa9fdd81a3036bee484c7e81544bb1f7b05
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital FingerprintzealZM8w-efee2e179c4f088b82874aa091f06a01